NETZSCH Pumps & Systems announces the NEMO R. MY Magnetically Coupled Pump, a pump designed to meet the most demanding requirements of industries requiring leak-free pumping solutions.
August 2025 marks two years since revisions to Annex 1 of the European Union’s Good Manufacturing Practice (GMP) guidelines were introduced. Niamh Bissett, director, business transformation at West Pharmaceutical Services discusses.
Asimov, the synthetic biology company advancing the design and manufacture of therapeutics, is collaborating with Cytiva to provide customers with an integrated offering for optimised biologics production.
Orchestra BioMed Holdings has announced that FDA has approved its Investigational Device Exemption amendment to initiate an updated design of the Company’s planned Virtue SAB in the Treatment of Coronary ISR Trial.
Amerikooler highlights its XPS Insulation, engineered to deliver "unparalleled" thermal performance, durability, and environmental responsibility across a wide range of applications.
Sail Biomedicines’ Kerry Benenato and Rajesh Ramaswamy discuss the roles artificial intelligence (AI) can play in informing programmability, using the example of Sail’s tailored Endless RNATM (eRNATM) medicines.
The Novo Nordisk Foundation has announced the latest edition of its annual Challenge Programme, where for the first time it is inviting researchers from outside Denmark, in the European Schengen area, Ireland and the UK.
Metrion Biosciences, a preclinical contract research organisation (CRO), has announced the launch of its validated, high-throughput NaV1.9 screening assay to advance discovery and development of novel pain therapeutics.
Thermo Fisher Scientific is employing an enhanced platform technology and a new CHO K-1 cell line that can reduce timelines to Investigational New Drug (IND) filing from 13 to nine months.
Ramesh Jagadeesan, vice president, head of analytical services at Recipharm shares his insights on the role of analytical services in drug development.
Ferrer, a pharmaceutical company with an increasing focus on rare neurological diseases, and Prilenia Therapeutics B.V., a clinical-stage biotech company, have announced the signing of a strategic co-development and license agreement.
